Abstract | OBJECTIVES: Recently, shikonin derivatives from Lithospermum erythrorhizon have been suggested as potential chemotherapeutic agents against numerous types of cancers in addition to their traditional uses, e.g., as anti-inflammatory agents. Acetylshikonin, one of shikonin derivatives, has also been reported to possess anticancer activity. However, few studies of the effectiveness of acetylshikonin against cancer cells have been conducted, and there are no studies of oral cancers. In this study, we investigated the usefulness of acetylshikonin as a treatment regimen for oral cancers by observing the growth inhibitory function of acetylshikonin and the involved mechanisms. DESIGNS: RESULTS: We observed that acetylshikonin significantly suppressed the growth of OSCC cells by inducing apoptotic cell death, and acetylshikonin affected the viability of a normal keratinocyte cell line HaCaT to a lesser degree, suggesting that acetylshikonin may be a good chemotherapeutic reagent with less toxicity to normal tissues. In addition, we found that acetylshikonin-induced apoptosis of OSCC cells is mediated by ROS as well as G2 cell cycle arrest. ROS production in response to acetylshikonin treatment enhanced the phosphorylation of JNK and p38 MAPK, which are in the major pathways of apoptotic cell death mechanisms. CONCLUSIONS: In summary, our data suggest that acetylshikonin is a strong candidate for use as a selective chemotherapeutic agent for the treatment of OSCC.
|
Authors | Da Jeong Kim, Ji Hye Lee, Hae Ryoun Park, Young Whan Choi |
Journal | Archives of oral biology
(Arch Oral Biol)
Vol. 70
Pg. 149-157
(Oct 2016)
ISSN: 1879-1506 [Electronic] England |
PMID | 27371806
(Publication Type: Journal Article)
|
Copyright | Copyright © 2016 Elsevier Ltd. All rights reserved. |
Chemical References |
- Anthraquinones
- Antineoplastic Agents
- Reactive Oxygen Species
- p38 Mitogen-Activated Protein Kinases
- MAP Kinase Kinase 4
- acetylshikonin
|
Topics |
- Anthraquinones
(pharmacology)
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects)
- Carcinoma, Squamous Cell
(drug therapy, metabolism, pathology)
- Cell Cycle
(drug effects)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Enzyme Activation
(drug effects)
- G2 Phase Cell Cycle Checkpoints
(drug effects)
- Humans
- MAP Kinase Kinase 4
(metabolism)
- Metabolic Networks and Pathways
(drug effects)
- Mouth Neoplasms
(drug therapy, pathology)
- Reactive Oxygen Species
(metabolism)
- p38 Mitogen-Activated Protein Kinases
(metabolism)
|